- Condition: Hemophilia A
Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Biological: PEGylated Recombinant Factor VIII
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation; Baxter Innovations GmbH
Recruiting - verified May 2012 - Condition: Relapsing Multiple Sclerosis
Intervention:
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Enrolling by invitation - verified May 2012 - Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Rebif; Other: other disease modifying therapies (DMT)
Sponsors: Merck KGaA; Merck KGaA; Merck Serono Limited, UK
Recruiting - verified May 2012 - Conditions: Anxiety; Depression
Interventions: Behavioral: Individual Career Management (ICM); Behavioral: Standard Care
Sponsors: South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust
Recruiting - verified May 2012 - Conditions: Heart Failure; Endothelium
Intervention: Drug: Urocortin 2, Urocortin 3 and Substance P
Sponsors: University of Edinburgh; University of Edinburgh; NHS Lothian
Not yet recruiting - verified May 2012 - Condition: Actinic Keratosis
Interventions: Drug: Ingenol mebutate gel, 0.015%; Drug: Vehicle gel
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified May 2012 - Condition: Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Not yet recruiting - verified May 2012 - Condition: HPV-16 +ve Oropharyngeal Carcinoma
Intervention: Biological: ADXS11-001
Sponsors: University of Liverpool; University of Liverpool; Aintree University Hospitals NHS Foundation Trust; Cancer Research UK; Advaxis, Inc.; Recipharm AB
Recruiting - verified May 2012 - Condition: Lower Eyelid Entropion
Interventions: Procedure: 7/0 vicryl suture; Procedure: 5/0 vicryl test suture
Sponsors: The Royal Bournemouth Hospital; The Royal Bournemouth Hospital
Completed - verified May 2012 - Condition: Stroke
Interventions: Behavioral: Usual care; Behavioral: Overground visual cue training; Behavioral: Treadmill visual cue training
Sponsors: University of Salford; University of Salford; University of Birmingham; Nottingham Clinical Trials Unit; Stroke Research Network; The University of Newcastle, Australia
Not yet recruiting - verified May 2012 - Condition: Multiple Sclerosis
Interventions: Drug: PR Fampridine; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Conditions: Multiple Conditions; Coronary Heart Disease; Diabetes; Hypertension; Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: University of Southampton; University of Southampton
Not yet recruiting - verified May 2012 - Condition: Reflux Oesophagitis
Intervention: Drug: YF476
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; Ferring Pharmaceuticals
Completed - verified May 2012 - Condition: Reflux Oesophagitis
Interventions: Drug: YF476; Drug: Omeprazole
Sponsors: Trio Medicines Ltd.; Trio Medicines Ltd.; Ferring Pharmaceuticals
Completed - verified May 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Sativex; Drug: Placebo
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.
Completed - verified May 2012 - Condition: Atrial Flutter
Interventions: Procedure: Radiofrequency ablation utilising the ECI contact software; Procedure: Radiofrequency ablation without the use of ECI contact data
Sponsors: Oxford University Hospitals NHS Trust; Oxford University Hospitals NHS Trust
Recruiting - verified May 2012 - Condition: Cardiovascular Health
Interventions: Other: Yoga; Other: Usual care
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified May 2012 - Condition: Postoperative Delirium
Intervention: Other: Bedside Mirrors Intervention
Sponsors: Papworth Hospital NHS Foundation Trust; Papworth Hospital NHS Foundation Trust
Not yet recruiting - verified May 2012 - Condition: Obesity
Interventions: Other: Breakfast Study; Other: fMRI Study
Sponsors: University of Aberdeen; University of Aberdeen; European Union
Recruiting - verified May 2012 - Conditions: Neoplasm Metastasis; Neoplastic Processes; Neoplasm Recurrence, Local; Neoplasm, Residual; Pain
Intervention: Radiation: Radiosurgery
Sponsors: Wuerzburg University Hospital; Wuerzburg University Hospital; Royal Marsden NHS Foundation Trust
Active, not recruiting - verified May 2012 - Condition: Primary Hyperparathyroidism
Intervention: Device: Near infrared fluorescence detection
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust
Not yet recruiting - verified May 2012 - Condition: Patients Requiring Forefoot Surgery
Interventions: Device: Darco shoe; Device: Podalux shoe; Device: Standard dressing shoe
Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust
Not yet recruiting - verified May 2012 - Condition: Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Laser
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2140023 Monohydrate (Reference); Drug: LY2140023 Monohydrate (Test - Low); Drug: LY2140023 Monohydrate (Test - Medium); Drug: LY2140023 Monohydrate (Test - High)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Metabolic Syndrome
Intervention: Drug: Pitavastatin
Sponsors: Kowa Research Europe; Kowa Research Europe
Recruiting - verified May 2012 - Conditions: Mental Health Wellness 1; Pregnancy; Mother-Child Relations
Interventions: Other: Mellow Bumps; Other: Chill-out in Pregnancy
Sponsors: University of Glasgow; University of Glasgow
Not yet recruiting - verified May 2012 - Condition: Idiopathic Pulmonary Arterial Hypertension
Interventions: Drug: (Pyr1)apelin-13; Drug: Saline
Sponsors: Imperial College London; Imperial College London
Recruiting - verified April 2012 - Condition: Lung Cancer - Malignant Pleural Mesothelioma
Interventions: Drug: Ganetespib; Drug: Placebo
Sponsors: University College, London; University College, London; Cancer Research UK
Not yet recruiting - verified May 2012 - Condition: Hereditary Haemorrhagic Telangiectasia
Interventions: Other: Aeroplane flight in the past- no active intervention for study; Other: Questionnaire
Sponsors: Imperial College London; Imperial College London
Completed - verified April 2012 - Condition: Paediatric Dentistry
Interventions: Procedure: compensatory extraction of upper FPMs; Procedure: no compensatory extraction of Upper FPMs
Sponsors: University of Dundee; Stephen McSwiggan; NHS Tayside
Not yet recruiting - verified May 2012 - Condition: Healthy
Interventions: Dietary Supplement: Dietary supplement of iron; Drug: Ferrous sulphate
Sponsors: Imperial College London; Imperial College London
Active, not recruiting - verified April 2012 - Condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
Intervention: Drug: LCQ908
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012 - Condition: Healthy
Interventions: Dietary Supplement: 2 portions of fruit and vegetables per day; Dietary Supplement: 5 portions of fruit and vegetables per day; Dietary Supplement: 8 portions of fruit and vegetables per day
Sponsors: Queen's University, Belfast; Queen's University, Belfast
Recruiting - verified May 2012 - Condition: Infertility
Intervention:
Sponsors: Origio A/S; Origio A/S; Novocellus Ltd.; Signifikans ApS
Recruiting - verified April 2012 - Condition: Carpal Tunnel Syndrome
Intervention: Device: EMS Therasonic 460 Primo Ultrasound therapy
Sponsors: East Kent Hospitals University NHS Foundation Trust; East Kent Hospitals University NHS Foundation Trust
Not yet recruiting - verified May 2012 - Condition: Mild to Moderate Psoriasis
Interventions: Other: TTOP; Other: non-TTOP
Sponsors: Reich, Kristian, M.D.; Kristian Reich, MD; LEO Pharma
Recruiting - verified May 2012 - Conditions: Cancer; Non Small Cell Lung Cancer
Interventions: Drug: Vandetanib, Selumetinib; Drug: Vandetanib, Selumetinib; Drug: Vandetanib, Selumetinib; Drug: Vandetanib, Selumetinib
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Differentiated Thyroid Cancer
Intervention:
Sponsors: Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle-upon-Tyne Hospitals NHS Trust
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: N(t)RTI) + boosted protease inhibitors (PI/r); Drug: maraviroc + boosted protease inhibitors (PI/r); Drug: maraviroc + N(t)RTI)
Sponsors: Kirby Institute; Kirby Institute
Not yet recruiting - verified April 2012 - Condition: Advanced Solid Tumours
Intervention: Biological: AT13148
Sponsors: Cancer Research UK; Cancer Research UK
Not yet recruiting - verified April 2012 - Condition: Bone Metastasis
Intervention: Device: MR-HIFU treatment for pain palliation of bone metastases
Sponsors: Philips Healthcare; Philips Healthcare
Not yet recruiting - verified April 2012 - Condition: Atrial Fibrillation
Intervention: Device: THERMOCOOL® SMARTTOUCH™ Catheter
Sponsors: Barts & The London NHS Trust; Barts & The London NHS Trust
Recruiting - verified April 2012 - Conditions: Myocardial Infarction; Reperfusion Injury; Myocardial Ischemia; Cardiovascular Diseases
Interventions: Drug: Sodium Nitrite; Drug: Sodium Chloride Placebo
Sponsors: Barts & The London NHS Trust; Barts & The London NHS Trust; Queen Mary University of London
Recruiting - verified April 2012 - Conditions: Primary Bile Acid Malabsorption; Secondary Bile Acid Malabsorption; Chronic Diarrhoea
Intervention: Drug: Obeticholic acid
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Other: CyberKnife prostate SBRT delivered by the CyberKnife in 36.25Gy in 5 fractions or 38Gy in 4 fractions
Sponsors: Accuray Incorporated; Accuray Incorporated; Royal Marsden NHS Foundation Trust, London, UK; Mount Vernon Cancer Center, East & North Herts NHS Trust,Northwood,Middlesex, UK; Centre Oscar Lambret, Lille, France; Charite University, Berlin, Germany; Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; The Institute of Cancer Research, Sutton, Surrey, UK
Recruiting - verified May 2012 - Condition: Cardiovascular Disease
Intervention:
Sponsors: Queen Mary University of London; Queen Mary University of London; King's College London
Not yet recruiting - verified April 2012 - Condition: Achilles Tendinopathy
Interventions: Procedure: Ultrasound guided injection of steroid and local anaesthetic; Procedure: High volume saline injection; Behavioral: exercise programme
Sponsors: Leeds Comunity Healthcare NHS Trust; Leeds Comunity Healthcare NHS Trust; National Insitute of Health Research FSF funding
Recruiting - verified April 2012 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Cervical Cancer; Endometrial Cancer; Esophageal Cancer; Fallopian Tube Cancer; Gastric Cancer; Ovarian Cancer; Sarcoma; Vaginal Cancer; Vulvar Cancer
Intervention:
Sponsors: Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Surrey
Recruiting - verified April 2012 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012 - Condition: Cardiovascular Disease
Intervention: Dietary Supplement: High/ Low Epicatechin Apples/ Apple Extract/ Granules
Sponsors: Queen's University, Belfast; Queen's University, Belfast
Recruiting - verified April 2012 - Condition: Cough
Interventions: Drug: GSK2339345 (Inhaled) Single Dose; Other: Placebo (Inhaled) Single Dose; Drug: GSK2339345 (Inhaled) Repeat Dose; Other: Placebo (Inhaled) Repeat Dose
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Gut Microbiota; Immune Function
Interventions: Dietary Supplement: Synbiotic; Dietary Supplement: Placebo; Dietary Supplement: Prebiotic; Dietary Supplement: Probiotic
Sponsors: University of Reading; University of Reading; Danisco
Completed - verified April 2012 - Conditions: Meningitis; Meningococcal Disease; Septicaemia
Interventions: Biological: MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis); Biological: 1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)
Sponsors: University of Oxford; University of Oxford
Not yet recruiting - verified May 2012 - Condition: Cardiovascular Function
Intervention: Biological: Typhoid vaccine
Sponsors: Queen Mary University of London; Queen Mary University of London
Recruiting - verified April 2012
 |
Paid Clinical Trials in the United Kingdom |
Clinical Trial Locations 